DNA Stock Recent News

Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomic Revolution ETF (ARKG) is down by 79% from the same period.

Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel.

Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target still implies more than 100% upside.

The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks.

Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.

Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.

Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.